Galmed Pharmaceuticals Ltd. (GLMD) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
GLMD currently has 6.56M outstanding shares. with significant dilution risk as 15.2M authorized shares could dilute existing holders by 231.0%. The company has significantly diluted shareholders by 431.64% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 31, 2026 |
POS AM filing: This prospectus relates to the offer and sale of up to 7,250,000 of our ordinary shares, par value NIS 1.80 per share, by YA II PN, LTD. |
6.6M | 15M |
| Mar 31, 2026 |
20-F filing | 6.6M shares outstanding |
6.6M | 23M |
| Aug 18, 2025 |
F-1 filing: This F-1 filing registers 7,500,000 ordinary shares offered by the selling shareholder YA II PN, LTD. The ordinary shares are to be issued pursuant to the Standby Equity Purchase Agreement dated August 30, 2024. The company may receive up to $20.0 million in aggregate gross proceeds from sales of their ordinary shares to YA. |
5.5M | 24M |
| Apr 02, 2025 |
20-F filing | 1.7M shares outstanding |
1.7M | 20M |
| Apr 02, 2025 |
POS AM filing: This prospectus relates to the offer and sale of up to 809,217 of our ordinary shares, par value NIS 1.80 per share, by YA II PN, LTD. |
2.3M | 19M |
| Nov 14, 2024 |
F-3 filing: Galmed Pharmaceuticals LTD. is filing an F-3 to offer, issue and sell from time to time up to US $200,000,000 of its ordinary shares, including in the form of warrants to purchase ordinary shares, including in the form of subscription rights, debt securities and a combination of such securities, separately or as units, in one or more offerings. |
1.7M | 21M |
| Oct 21, 2024 |
F-1 filing: This F-1 filing relates to the offer and sale of up to 1,000,000 ordinary shares by YA II PN, LTD. with Galmed Pharmaceuticals Ltd. |
1.5M | 21M |
| Aug 30, 2024 |
F-1 filing: Galmed Pharmaceuticals Ltd. is offering up to 416,667 ordinary shares through a selling shareholder, YA II PN, LTD., with the company potentially receiving up to $10 million from sales of ordinary shares to YA under a Purchase Agreement. |
640K | 21M |
| Apr 04, 2024 |
20-F filing | 5.0M shares outstanding |
5M | 16M |
| Nov 22, 2023 |
POS AM filing: This POS AM filing registers ordinary shares issuable upon exercise of placement agent warrants issued as compensation as part of a public offering in July 2023. |
25M | 0 |
| Nov 01, 2023 |
POS AM filing: This is a POS AM filing registering ordinary shares issuable upon exercise of placement agent warrants and common warrants. |
25M | 0 |
| Mar 29, 2023 |
20-F filing | 25.1M shares outstanding |
25M | 0 |
| May 02, 2022 |
20-F filing | 24.6M shares outstanding |
25M | 0 |
| Mar 26, 2021 |
F-3 filing: This is an F-3 filing to register securities for sale under a shelf registration process, including ordinary shares, warrants, subscription rights, debt securities, or a combination thereof, up to an aggregate offering price of $300,000,000 and an at the market offering of ordinary shares for up to $50,000,000. |
25M | 0 |
| Mar 18, 2021 |
20-F filing | 21.3M shares outstanding |
21M | 0 |
| Mar 12, 2020 |
20-F filing | 21.1M shares outstanding |
21M | 0 |